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Background: Dobesilate (2,5-dihydroxyphenyl sulfonate, DHPS) was recently identified as the most potent member
of a family of fibroblast growth factor (FGF) inhibitors headed by gentisic acid, one of the main catabolites of
aspirin. Although FGFs were first described as inducers of angiogenesis, they were soon recognized as broad
spectrum mitogens. Furthermore, in the last decade these proteins have been shown to participate directly in the
onset of inflammation, and their potential angiogenic activity often contributes to the inflammatory process in vivo.
The aim of this work was to evaluate the anti-inflammatory, anti-angiogenic and anti-tumoral activities of the
derivative of DHPS obtained by acetoxylation of its two hydroxyl groups (2,5-diacetoxyphenyl sulfonate; DAPS).
Methods: Anti-inflammatory, anti-angiogenic and anti-tumoral activities of DHPS and DAPS were compared using
in vivo assays of dermatitis, angiogenesis and tumorigenesis. The effects of both compounds on myeloperoxidase
(MPO) and cyclooxygenase (COX) activities, cytokine production and FGF-induced fibroblast proliferation were also
determined.
Results: Topical DAPS is more effective than DHPS in preventing inflammatory signs (increased vascular permeability,
edema, leukocyte infiltration, MPO activation) caused by contact dermatitis induction in rat ears. DAPS, but not DHPS,
effectively inhibits COX-1 and COX-2 activities. DAPS also reduces the increase in serum cytokine concentration induced
by lipopolysaccharide in rats. Furthermore, DAPS displays higher in vivo efficacy than DHPS in inhibiting FGF-induced
angiogenesis and heterotopic glioma progression, with demonstrated oral efficacy to combat both processes.
Conclusions: By inhibiting both FGF-signaling and COX-mediated prostaglandin synthesis, DAPS efficiently breaks the
vicious circle created by the reciprocal induction of FGF and prostaglandins, which probably sustains undesirable
inflammation in many circumstances. Our findings define the enhancement of anti-inflammatory, anti-angiogenic and
anti-tumoral activities by diacetyloxyl derivatization of the FGF inhibitor, dobesilate.
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Prostaglandins (PGs) are local mediators of inflam-
mation, the synthesis of which is controlled by cyclooxy-
genases (COXs). The COX-1 isoform is constitutively
expressed while COX-2 expression is induced in specific
pathophysiological conditions or in response to in-
flammatory stimuli [1]. Non-steroidal anti-inflammatory
drugs (NSAIDs), such as acetylsalicylic acid (ASA; as-
pirin), achieve their anti-inflammatory effects, at least in
part, by inhibiting prostaglandin production [2]. Indeed,
ASA irreversibly inhibits COX activity by acetylating a
serine residue at the active centre of the enzyme [3]. Up-
regulation of COX-2 occurs in many diseases in which
chronic inflammation plays a key role. Moreover, COXs
have been widely implicated in tumorigenesis, a process
to which they contribute by upregulating the expression
of pro-angiogenic cytokines, vascular endothelial cell
growth factor (VEGF) and fibroblast growth factor (FGF)
[4-7], making them responsible for the pathological neo-
vascularization of tumors. VEGF and FGF can also induce
the expression of COX-2 and phospholipase A2, as well as
the ensuing production of PG in endothelial cells, creating
a positive feedback loop typical of chronic diseases [8,9].
Dobesilate (2,5-dihydroxyphenyl sulfonate, DHPS) is a
small synthetic molecule with a good safety profile that
has been widely used to treat diabetic retinopathy and
chronic venous insufficiency [10,11], although its me-
chanism of action remained unknown and its efficacy
has been criticized [12]. DHPS was rediscovered as the
most active member of a family of compounds headed
by gentisic acid, the catabolite of aspirin, which inhibit
FGF-induced cell proliferation, migration and angio-
genesis in distinct biological scenarios. These inhibitors
were recently shown to interact with the heparin-
binding domain of representative members of the FGF
family and with FGF receptors (FGFRs), inducing
structural alterations that block their interaction with
heparin, and that interfere with the formation of the
complex that triggers physiological cell responses to
FGF [13].
Although initially classified as a broad-spectrum mito-
gen, FGF is now also believed to trigger inflammation,
and it is closely associated with the inflammasome,
which promotes neovascularization by rapidly inducing
an inflammatory phenotype in microvascular endothelial
cells [14,15]. Either directly or through FGF inhibition
[16] DHPS also inhibits VEGF activity [17] and, accord-
ingly, DHPS should also interfere with the PG/FGF-
VEGF feedback loop described above. Indeed, these
antagonistic effects should be taken into account when
considering the preclinical efficacy of DHPS in treating
gliomas [13,18], and the clinical benefits of using DHPS
in humans to treat ocular inflammatory diseases [19,20],
allergic contact dermatitis [21] and pathologies relatedto angioproliferative conditions, such as psoriasis [22]
and basal cell carcinoma [23].
Gliomas are devastating brain tumors with exacer-
bated proliferation, angiogenesis and invasiveness [24]
that display poor prognosis even after the introduction
for its treatment of temozolomide in addition to ra-
diotherapy [25]. Thus, the development of new stra-
tegies seems definitely appropriate. Considering the key
role of inflammation in angiogenesis [26] and glioma
[27,28], we explored whether anti-inflammatory pro-
perties could be added to drugs that interfere with gli-
oma growth by inhibiting FGF [18] which may allow a
better management of gliomas, as well as of other
angiogenesis-dependent diseases. The search for novel
anti-inflammatory drugs has identified many acetyloxy-
phenyl compounds that are effective inhibitors of COX
activity [29,30]. DHPS contains a phenyl ring with two
hydroxyl groups, which is readily accessible to intro-
duce acetyloxyl groups, which should confer chemical
properties similar to those of the aforementioned acety-
loxyphenyl chemicals. With these premises our aim
was to evaluate the anti-inflammatory activities of the
acetyloxyl derivative of DHPS, 2,5-diacetyloxyphenyl
sulfonate (DAPS) in in vivo and in vitro assays and its
ability to inhibit angiogenesis and heterotopic glioma
progression in animal models. Accordingly, we show
that the acetoxylation of DHPS yields a compound with
enhanced anti-inflammatory activity in different in vivo
and in vitro circumstances, as well as inhibitory effects
on COX activity. These results pave the way to develop
new potent anti-inflammatory compounds to treat nu-
merous pathologies.Methods
Chemicals
Potassium 2,5-dihydroxyphenyl sulfonate (DHPS) was
obtained from Sigma-Aldrich (Saint Louis, MO) and
reagent-grade potassium 2,5-diacetoxyphenyl sulfonate
(DAPS) was purchased from Aurigene (Bangalore, India).
The chemical structures are shown in Figure 1A.Animals
Male Sprague-Dawley rats (250 g to 350 g) were obtained
from the animal facilities of the Hospital Universitario
Ramón y Cajal and they were used for all the animal
studies. Studies were performed in accordance with the
Declaration of Helsinki, and with the EU guidelines for
the handling and care of laboratory animals. All the
protocols were approved by the Ethics Committee for
Animal Experimentation of the Hospital Universitario
Ramón y Cajal (Acta 2/2010). Animals were anesthe-
tized by intraperitoneal injection of 50 mg/kg ketamine
and 4 mg/kg diazepam.
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Figure 1 Chemical structures of potassium 2,5-dihydroxyphenyl
sulfonate (DHPS: A) and potassium 2,5-diacetoxyphenyl
sulfonate (DAPS: B). Panels C and D show representative images
illustrating the effects of DHPS (C) and DAPS (D) on dermatitis of rat
ears induced by the application of benzalkonium chloride. After
induction of dermatitis in both ears, the right ear was treated
topically with DHPS (5% w/v; eq. to 0.22 mmol/ml) or DAPS (5% w/v;
eq. to 0.16 mmol/ml), and the left ear with the vehicle alone (glycerol).
The extent of dermatitis (vascular hyperpermeability) was revealed by
intravenous injection of Evans blue dye. In panel E the inhibitory
effects of DHPS (5%; eq. to 0.22 mmol/ml) and DAPS (2.5% and 5%;
eq. to 0.08 and 0.16 mmol/ml) on dermatitis are quantified, expressing
the data as the mean ± SEM of the percentage of blue-stained area
relative to the total area of the ear. The number of animals used for
each determination is shown in parentheses: ***p < 0.001 vs. vehicle,
† p < 0.05 vs DHPS by one-factor ANOVA followed by Student-
Newmann-Keuls test.
Angulo et al. Journal of Translational Medicine  (2015) 13:48 Page 3 of 14Dermatitis model
Dermatitis was induced by the application of benzalko-
nium chloride (BZK; 5% w/v solution) in a 1:5 mixture of
olive oil:acetone along the back of both ears (40 μl/ear) of
anesthetized rats. Thirty minutes after the application of
BZK, 40 μl of DHPS (5% w/v) or DAPS (2.5% or 5%) in
glycerol were applied topically to the back of the right ear,
while glycerol alone (vehicle) was applied to the left ear as
a control. Fifteen minutes later, 400 μl of Evans blue dye
solution (0.5%; w/v) were injected into the jugular vein,
this dye exclusively staining blue the areas of the skin with
altered vascular permeability that results in extravasation
of the dye. Twenty-four hours after the induction of
dermatitis photographs of the extended ears were taken
and the stained and total areas of the ear were determined
by image analysis (Motic Image Advanced 3.0, Xiamen,
China). The stained area of each ear was expressed relative
to the total area to determine the percentage of the ear
affected by dermatitis.
In another series of experiments, dermatitis was in-
duced on both ears of anesthetized rats as described
above and, 30 minutes after applying BZK, 2.5% DAPS
or the vehicle alone (glycerol, 40 μl) was applied to both
ears. Twenty-four hours after dermatitis induction, the
rats were anesthetized and both ears were excised for
histological evaluation (left) and to determine myeloper-
oxidase (MPO) activity (right).
Histological evaluation
Excised rat ears, gelatin sponges and subcutaneous gli-
omas were fixed by immersion in 4% paraformaldehyde
and embedded in paraffin to obtain 6 μm sections that
were deparaffinized in xylene, rehydrated through a series
of decreasing ethanol concentrations (100-70%) and finally
rinsed in distilled water. The deparaffinized tissue sections
were then stained with hematoxylin and eosin for histo-
logical examination.
Myeloperoxidase activity determination
Rat ears were frozen in liquid nitrogen immediately after
excision and stored at -80°C until MPO activity was deter-
mined as follows. The frozen ears were homogenized in
phosphate buffer containing 0.5% hexadecyltrimethylam-
monium bromide and, after three freeze/thaw/sonication
cycles, the samples were centrifuged at 13,000 × g for
20 minutes at 4°C. H2O2 (0.0005%) and O-dianisidine
(0.167 mg/ml) were added to the supernatants, and the ab-
sorbance was measured at 460 nm in a spectrophotometer
after incubating for 1 hour at room temperature. MPO acti-
vity was expressed as the absorbance units per mg of tissue.
COX inhibition
The inhibitory effects of drugs on cyclooxygenase (COX)
activity were determined using a commercially available
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Arbor, MI. Cat # 560131). COX-1 enzyme (ovine) in reac-
tion buffer (0.1 M Tris-HCl [pH 8.0], 5 mM EDTA, 2 mM
phenol) containing heme was incubated for 10 min at 37°C
in the presence or absence of acetylsalicylic acid (ASA),
DHPS or DAPS (1 to 100 μM). Similarly, COX-2 (human
recombinant) was incubated for 10 min at 37°C in the
same heme-containing reaction buffer in the presence or
absence of ASA, DHPS or DAPS (1 to 100 μM). Reactions
were triggered with 100 μM arachidonic acid, the reaction
substrate, and they were stopped after 2 min by adding
HCl. The prostanoid product was quantified by enzyme
immunoassay, using PGE2 as standard, and measuring the
absorbance at 405 nm. The data are expressed as the per-
centage of COX-1 or COX-2 activity recorded in the ab-
sence of inhibitors (100% activity) after subtracting the
background activity of heat-inactivated enzyme.
Determination of coagulation time
Sprague-Dawley rats were anesthetized and a catheter
was introduced into the left external jugular vein for
saline or drug infusion. The tail was then incised using a
disposable surgical blade and bleeding of the tail was
monitored by blotting with a filter paper every 30 s. The
time from incision to the cessation of bleeding (no blood
stains on the paper) was recorded [31]. Bleeding time
was measured before and 60 min after intravenous ad-
ministration of ASA (10 mg/kg), DHPS (10 mg/kg) or
DAPS (10 mg/kg).
Cytokine measurement
Rats were injected with lipopolysaccharide (LPS) from
E. coli (5 mg/kg, i.p.) or with the vehicle alone (0.9% NaCl,
i.p.; controls), and they were subsequently intraperitoneally
injected with the vehicle (0.9% NaCl), DHPS (100 mg/kg)
or DAPS (100 m/kg). Six hours after LPS injection, blood
was collected in dry tubes and the serum isolated by cen-
trifugation. Serum samples were immediately frozen and
maintained at -80°C until the serum concentrations of
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and
interleukin-1ß (IL-1ß) were determined by ELISA (R&D
Systems, Abingdon, UK).
Fibroblast proliferation assays
Inhibition of FGF-mediated mitogenesis was evaluated
in murine Balb/C 3 T3 fibroblasts, as described pre-
viously [13]. Fibroblasts seeded in 96-well plates were
stimulated with FGF-1 (0.64 ng/ml) in the presence of
myoinositolhexasulfate (MIHS; 100 μg/ml). Cultures
were incubated in the presence or absence (control) of
different concentration of DHPS or DAPS (3 μM to
1 mM) and allowed to proliferate for 48 h. Cells were
then counted by measuring the total amount of crystalviolet fixed by the cell nuclei by determining differential
absorbance at 595 nm.
In vivo angiogenesis
Sterile gelatin sponges (1 cm3; Curaspon Dental, Clinimed
Holding, Zwanenburg, The Netherlands) were moistened
with 200 μl of phosphate buffered saline (PBS) solution with
or without (controls) 25 μg/ml of heparin and 10 μg/ml of
FGF-1, and they were implanted subcutaneously in the
dorsal region of the neck of anaesthetized Sprague-Dawley
rats as described elsewhere [13]. After implantation, the
rats were randomly assigned to groups that received
0.3 ml of vehicle (tap water), DHPS (150 mg/kg) or DAPS
(150 mg/kg) twice a day by oral gavage (300 mg/kg/d). In
a separate assay, a dose-response relationship of the oral
effects of DAPS on in vivo angiogenesis was ascertained
by administering DAPS at 20, 50, 100 and 300 mg/kg/d.
After 7 days, the sponges were removed and sections
(6 μm) were obtained and then stained with hematoxylin/
eosin as above described. Six random fields (0.176 mm2)
from each sponge were evaluated to quantify the extent of
neovascularization using image analysis software (Motic
Images). The effects of the different treatments on vascu-
lar density, determined by the number of functional blood
vessels (those containing erythrocytes) per field, were
evaluated.
Rat model of subcutaneous glioma
Rat C6 glioma cells were cultured as described previously
[32,33]. C6 cells cultured to confluence in 75 cm2 flasks
were removed and implanted beneath the abdominal skin
of anesthetized rats. The presence of tumors in the im-
plantation area was determined 5 days after the implan-
tation of the tumor cells. Rats in which the existence of a
tumor was confirmed were randomly assigned for treat-
ment with vehicle (0.9% NaCl), DHPS (100 mg/kg/d) or
DAPS (100 mg/kg/d), administered by daily intraperito-
neal injection. In an additional series of experiments, oral
efficacy of DAPS was evaluated by administration of
vehicle (tap water) or DAPS (200 mg/kg/d) by gavage.
After 10 days of treatment, either intraperitoneal or oral,
the subcutaneous gliomas were removed, photographed,
weighed and their volume was calculated according to the
formula V = 4/3π•(D/2)•(d/2)2 (in mm3), where D is the
larger diameter and d is the smaller diameter, both
expressed in mm.
Determination of serum lactate dehydrogenase
Blood was collected from anesthetized rats at the mo-
ment of subcutaneous glioma extraction and from 8 age-
matched rats not bearing tumor (control rats) by cardiac
puncture. Blood was drained into dry tubes and the
serum isolated by centrifugation. Serum samples were
immediately frozen and maintained at -80°C until the
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mined by using a commercial kit (Architect c Systems,
Abbott, Abbott Park, IL, USA) following manufacturer’s
instructions.
Tumoral vascularization and apoptosis
For evaluating tumoral vascularization, tumor sections
(6 μm) were obtained and then stained with hema-
toxylin/eosin as above described. High-resolution images
of stained tumor sections were taken and number of
blood vessels and areas were determined using morpho-
metric software (Motic). Vascular density was calculated
as the total number of functional blood vessels relative
to total area of the tumor. Apoptosis was determined by
terminal 2′-deoxyuridine-5′-triphosphate (dUTP) nick-
end-labeling (TUNEL) assay in deparaffined tissue sections
(6 μm) of the subcutaneous gliomas. A fluorescence-based
commercial kit was used following manufacturer’s specifi-
cations (Promega Biotech Ibérica, Alcobendas, Spain). Per-
centage of apoptosis was calculated by counting apoptotic
cell nuclei (TUNEL-positive cells) relative to total number
of cell nuclei in six high-magnification visual fields (x400)
for each sample.
Results
DAPS is more effective than DHPS in inhibiting
dermatitis-induced inflammation
The dermatitis induced in rat ears by 5% BZK was asso-
ciated with an increase in vascular permeability, evident
through the extravasation of Evans blue dye that stains
the ears in blue (Figure 1C-D, left ears). Topical treat-
ment with DHPS (5%) or DAPS (5%) markedly inhibited
vascular permeability, both treatments diminishing the
intensity of the blue staining (Figure 1C-D, right ears).
When vascular permeability was quantified as the per-
centage of area stained, DHPS significantly reduced stai-
ning while DAPS induced a more significant reduction,
even when administered at half the concentration of
DHPS (Figure 1E).
In the absence of dye administration, a marked ery-
thematous response was observed 24 h after the induc-
tion of dermatitis with 5% BZK in rat ears (Figure 2A)
which was notably prevented by topical application of
DAPS (2.5%) (Figure 2B). A detailed histological cha-
racterization of the inflammatory response confirmed
that topic application of DAPS (2.5%) reduced the exten-
sive skin edema (Figure 2C-D) and leukocyte infiltration
(Figure 2E-H) associated with dermatitis in untreated
animals. Dermatomyositis was also observed in the
erector muscle of the ear after BZK-induced dermatitis
(Figure 2I) and likewise, it was prevented by DAPS
administration (Figure 2J). The involvement of leukocyte
infiltration in this inflammatory response was confirmed
by the significant elevation of MPO activity. This increasewas prevented by topical administration of DHPS (5%),
and more effectively with 2.5% DAPS (Figure 2K).
DAPS inhibits COX activity and its effects
DHPS (1 to 100 μM) had no significant inhibitory effect on
COX activity, whereas the acetyloxy derivative DAPS (1 to
100 μM) induced significant concentration-dependent in-
hibition of both COX-1 and COX-2 (Figure 3A-B). In fact,
DAPS was as potent as ASA in inhibiting COX-1 activity,
and even more efficient than ASA in inhibiting COX-2
(Figure 2A-B).
An increase in bleeding can be used to estimate the
decrease of thromboxane production by platelets as a
consequence of COX inhibition in these organelles. The
anti-thrombotic capacity of DAPS (10 mg/kg, i.v.) was
equivalent to, or greater than, that induced by intrave-
nous administration of ASA (10 mg/kg), and it was twice
that observed for the parent molecule, DHPS (10 mg/kg,
i.v.: Figure 3C).
DAPS reduces pro-inflammatory cytokine levels
Since, in addition to mediating local inflammatory pro-
cesses, FGF and COX could have an impact on systemic in-
flammation, we evaluated the effect of DHPS (100 mg/kg;
i.p.) and DAPS (100 mg/kg; i.p.) on the level of TNF-α, IL-6
and IL-1ß in a rat model of systemic inflammation. Pre-
cisely, the marked increase of the serum levels of TNF-α
caused by intraperitoneal injection of LPS (5 mg/kg) was
significantly attenuated by DHPS, and to a larger extent,
by DAPS administration (Figure 4A). LPS also mar-
kedly increased serum concentrations of IL-6 and IL-1ß.
Although DHPS showed a trend to reduce the elevation
of these cytokines, only DAPS was able to significantly
reduce the increase in IL-6 and IL-1ß caused by LPS
(Figure 4B-C).
Acetylated DHPS inhibits the mitogenic activity of FGF
in vitro and displays enhanced anti-angiogenic activity
in vivo
DAPS inhibited FGF-induced proliferation of 3T3 fibro-
blasts in vitro (Figure 5A), although with a higher IC50
than DHPS. This result is not completely surprising,
given the tight fit of the latter compound into a narrow
pocket at the surface of FGF-1 [13]. However, DAPS is
still a better FGF inhibitor than other compounds used
as leads in the DHPS discovery process, which have been
widely used to inhibit FGF-induced angiogenesis [34].
FGF-1 induced extensive angiogenesis in subcutaneously-
implanted gelatin sponges, which was drastically attenuated
by oral administration of DAPS or DHPS (Figure 5B-D),
although more so by DAPS (Figure 5G). The oral efficacy
of DAPS to inhibit FGF-induced angiogenesis in this
model and the dose-dependency of this effect is shown
in Figure 5H. This FGF-induced neovascularization is
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Figure 2 Representative histology showing the effects of topical treatment with 2,5-diacetoxyphenyl sulfonate (DAPS; 2.5%; eq. to
0.08 mmol/ml) on benzalkonium chloride-induced dermatitis in the rat ear. The first row shows the macroscopic appearance of both ears
of a rat treated with vehicle alone (glycerol: A) and those of a rat treated with DAPS (B), which evidently reduces the erythema caused by
dermatitis. In the second row, the tissue edema on the ear of a rat with dermatitis treated only with glycerol (C) was not observed in DAPS-
treated rats (D). The third row shows the intense leukocyte infiltration in a glycerol-treated rat ear (E), an effect that was clearly reduced by DAPS
treatment (F). Magnification of the boxed area in E and F reveals that in the capillaries of vehicle-treated rats, there are leukocytes adhered to
the endothelial cells, which rolled and extravasated to infiltrate the surrounding tissue (G), a feature not observed in the vessels of DAPS-treated
rats (H). The infiltration of leukocytes into the erector muscle of the ear in glycerol-treated rats (I) was also attenuated by DAPS treatment (J).
Magnifications: C-F, x100; G-H x400; I-J x200. Panel K shows the effects of topic treatment with 2,5-dihydroxyphenyl sulfonate (DHPS; 5%; eq. to
0.22 mmol/ml), DAPS (2.5%; eq. to 0.08 mmol/ml) or the vehicle alone (glycerol) on the myeloperoxidase (MPO) activity associated with benzalkonium
chloride-induced dermatitis on the rat ear. Dermatitis was not induced in the control group. MPO activity is expressed as the mean ± SEM of the
absorbance at 460 nm normalized to the weight (mg) of the tissue of the corresponding ear. The numbers of animals used is shown in parentheses:
**p < 0.01 vs. control; † p < 0.05, †† p < 0.01 vs. vehicle by one-factor ANOVA followed by Student-Newmann-Keuls test.
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Figure 3 Effects of acetylsalicylic acid (ASA; 1 to 100 μM),
potassium 2,5-dihydroxyphenyl sulfonate (DHPS; 1 to 100 μM)
and potassium 2,5-diacetoxyphenyl sulfonate (DAPS; 1 to
100 μM) on cyclooxygenase (COX)-1 (A) and COX-2 (B) activity.
Data are expressed as the percentage of the total COX activity
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0.05 mmol/kg), DHPS (10 mg/kg; eq. to 0.04 mmol/kg) and DAPS
(10 mg/kg; eq. to 0.03 mmol/kg) on bleeding time (BT) in anesthetized
rats. The data are expressed as the mean ± SEM of the percentage of
increase in BT with respect to the basal determination for each animal.
The numbers of rats used for the measurements are indicated in
parentheses: *p < 0.05 vs. ASA; † p < 0.05 vs. DHPS, by one-factor
ANOVA followed by Student-Newmann-Keuls test.
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Figure 4 Effects of intraperitoneal injection of potassium
2,5-dihydroxyphenyl sulfonate (DHPS; 100 mg/kg; eq. to
0.44 mmol/kg) or potassium 2,5-diacetoxyphenyl sulfonate (DAPS;
100 mg/kg; eq. to 0.32 mmol/kg) on the lipopolysaccharide
(LPS)-induced increase in tumor necrosis factor-α (TNF-α; A),
interleukin-6 (IL-6; B) and interleukin-1ß (IL-1ß; C) concentrations
in rat serum. Serum samples were obtained 6 h after LPS injection
(5 mg/kg; i.p.) and the data are expressed as the mean ± SEM
concentration of cytokine in pg/ml or ng/ml: * p < 0.05, **p < 0.01 vs.
LPS + vehicle, † p < 0.05 vs. LPS+DHPS, by one-factor ANOVA followed
by Student-Newmann-Keuls test.
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strong inhibition of FGF-induced angiogenesis by DAPS
was accompanied by a clear reduction of FGF-induced
leukocyte infiltration (Figure 5F).
Acetylated DHPS displays superior anti-tumoral activity
in vivo
Considering the above confirmed capacity of DHPS and
DAPS to inhibit angiogenesis and inflammation and
given the key roles of these processes in carcinogenesis,
the effects of DHPS and DAPS on tumoral progression
were evaluated. To estimate the relative anti-tumoral po-
tential of these two compounds, we used a well-known
heterotopic model of glioma. As seen in Figure 6A-C,
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Figure 5 Inhibition of FGF-1-induced mitogenesis in vitro and angiogenesis in vivo by potassium 2,5-dihydroxyphenyl sulfonate
(DHPS) and potassium 2,5-diacetoxyphenyl sulfonate (DAPS). Panel A shows the inhibition of mitogenesis induced by fibroblast growth
factor (FGF)-1 in quiescent Balb/c 3T3 fibroblasts treated with DHPS or DAPS. Representative microphotographs show how oral administration of
the vehicle alone (VEH; tap water: B), DHPS (300 mg/kg/day; eq. to 1.32 mmol/kg/d; C) and DAPS (300 mg/kg/day; eq. to 0.96 mmol/kg/d; D)
affect FGF-1-induced angiogenesis in gelatin sponges subcutaneously implanted in rats for 7 days. In the same assay, intense leukocyte
extravasation and infiltration can be observed in sponges containing FGF-1 when they are removed from vehicle-treated rats (E) but not from
DAPS-treated rats (F). The extent of neovascularization detected in phosphate buffered saline (PBS)- and FGF-1-containing sponges removed from rats
treated with vehicle, DHPS or DAPS can be quantified (G). In a separate assay (H) the dose-response relationship of the effects of orally administered
DAPS is shown (20 to 300 mg/kg/day; eq. to 0.06 to 0.96 mmol/kg/d), expressing the data as the mean ± SEM number of functional vessels per field,
determined in 6 randomly acquired fields per specimen. The number of rats used for each measurement is indicated in parentheses: ***p < 0.001 vs.
neovascularization in the absence of FGF-1; ††† p < 0.001 vs. FGF-1 + VEH; §§ p < 0.01 vs. FGF-1 + DHPS by one-factor ANOVA followed by
Student-Newmann-Keuls test. Magnifications: B-D, x200; E-F, x400.
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Figure 6 Effects of intraperitoneal administration of potassium 2,5-dihydroxyphenyl sulfonate (DHPS) and potassium 2,5-diacetoxyphenyl
sulfonate (DAPS) on the progression of tumors established in rats by subcutaneous implantation of rat glioma C6 cells (5 × 105 cells).
Photographs show tumors removed from rats treated with vehicle (0.9% NaCl; n = 11; A), DHPS (100 mg/kg/d; eq. to 0.44 mmol/kg/d, i.p. for
10 days; n = 12; B), or DAPS (100 mg/kg/d, eq. to 0.32 mmol/kg/d, i.p. for 10 days; n = 13; C). Treatment began once the presence of a tumor
was verified on the fifth day after glioma cell implantation. Tumors were removed after 10 days of treatment and the empty spaces in panel C
correspond to tumors that had completely regressed after DAPS treatment (N.D., not detected). A 10 mm bar is displayed in each image.
Panels D and E show the quantification and comparison of the volumes and weights, respectively, of the tumors developed in rats treated with
vehicle (VEH), DHPS or DAPS. The data are expressed as the mean ± SEM. numbers of animals are shown in parenthesis. *p < 0.05; **p < 0.01;
***p < 0.001 vs. VEH; † p < 0.05 vs. DHPS, by one-factor ANOVA followed by Student-Newman-Keuls test. Panel F shows the effects of subcutaneous
glioma development and the treatment with DHBS and DAPS on serum concentrations of lactate dehydrogenase (LDH) in rats. The data are expressed
as the mean ± SEM of the percentage of serum LDH detected in control, not bearing glioma, rats (CON). Numbers of animals are shown in parenthesis.
*p < 0.05; **p < 0.01; vs. CON; † p < 0.05 vs. VEH, by one-factor ANOVA followed by Student-Newman-Keuls test.
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NaCl) were larger than those in rats treated with DHPS
(100 mg/kg/day; i.p.) or DAPS (100 mg/kg/day; i.p.). Rats
that received DHPS also exhibited larger tumors than
those treated with DAPS, and indeed, four rats that re-
ceived DAPS were tumor-free by the end of treatment,
despite the fact that all the rats developed comparable
tumors prior to treatment. By contrast, none of the tu-
mors were fully eliminated in the animals administered
the vehicle alone or DHPS. Quantification of the tumor
volume confirmed that tumor progression was signifi-
cantly inhibited in DHPS-treated rats, an effect that wasfurther enhanced in DAPS-treated rats (Figure 6D).
Evaluation of the tumor weight yielded similar results,
although the reduction in weight was only significant in
rats treated with DAPS (Figure 6E). This attenuated
effect may be explained by the existence of necrotic pro-
cesses in vehicle-treated tumors, a frequently-observed
phenomenon that diminishes tumor density as the tu-
mor volume increases. In fact, the serum concentrations
of lactate dehydrogenase (LDH), which is a marker of
tumoral necrosis [35,36], are significantly increased in
vehicle treated rats with subcutaneous gliomas when
compared to healthy not bearing glioma rats. Serum
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reduced by DHPS treatment and normalized by treating
with DAPS (Figure 6F).
Furthermore, DAPS displayed anti-tumoral efficacy
also when orally administered (Figure 7). Oral adminis-
tration of DAPS (200 mg/kg/d) resulted in reduced pro-
gression of subcutaneous gliomas induced by C6 cell
implantation in rats (Figure 7A). This was confirmed by
the significant reduction in tumor volume and weight
after the treatment with DAPS (Figure 7B). A strong
leukocyte infiltration from peritumoral vessels was ob-
served in vehicle-treated rats that was notably reduced
in rats treated with DAPS (Figure 7C). Inhibition of tu-
moral progression by oral DAPS was accompanied by a
reduction of tumor vascularization (Figure 7D) and an
increase in tumor apoptosis (Figure 7E). Oral treatment
with DAPS for 10 days did not cause signs of toxicity since
weight gain of animals treated with DAPS was not differ-
ent from that observed in vehicle treated animals. Baseline
weights just before C6 implantation were 332 ± 12 g and
319 ± 14 g for vehicle- and DAPS-treated groups,
respectively, while final weights 15 days afterwards,
including the 10-days treatment period, were 374 ± 15 g
and 373 ± 13 g for vehicle- and DAPS-treated groups,
respectively.
Discussion
In the present study we demonstrate that acetate esteri-
fication of the two hydroxyl groups of DHPS generates a
derivative, DAPS, which inhibits FGF and COX, and that
exhibits anti-coagulant, anti-inflammatory (local and sys-
temic), anti-angiogenic and anti-tumoral activities that
are considerably more potent than those of DHPS.
These enhanced properties of DAPS were not totally un-
expected, as they are regularly observed after COX in-
hibition, and the modifications introduced confer DAPS
with the typical chemical features of phenolic COX in-
hibitors [29,30]. However, the fact that some of these
properties are already present in DHPS, which does not
inhibit COX, is indeed surprising. Nonetheless, gentisic
acid was recently described as the head of a family of
potent FGF inhibitors, the most active member of which
is DHPS [13]. Accordingly, these unexpected properties
may merely be a consequence of FGF inhibition.
The role of FGFs in inflammatory processes has re-
ceived little attention due to their important mitogenic
activities in many biological processes, and their modu-
latory role during embryonic development and differen-
tiation. Nonetheless, there is significant evidence that
FGFs are involved in inflammation. As early as 1990, a
T-cell-dependent increase in FGF-1 expression was de-
scribed in the inflamed joints of patients with rheu-
matoid arthritis, and it was directly correlated with the
extent and intensity of inflammation [37]. Subsequently,upregulation of FGF-1 was described in allografts under-
going chronic rejection [38] and in renal inflammation
[39], while elevated levels of circulating FGF-2 were re-
ported in patients with inflammatory bowel disease [40]
and eosinophilic esophagitis [41]. The pericardial fluid of
patients with inflammatory pericardial disease also con-
tains increased levels of FGF-2 [42]. The anti-inflammatory
activity of DHPS in dermatitis model confirms the contri-
bution of FGF to inflammation. The added ability of the
acetyloxy derivative DAPS to inhibit COX activity to-
gether with its inhibitory activity on FGF would explain
the enhanced anti-inflammatory properties of this com-
pound over its parental molecule. In addition to its key
role in local inflammatory responses, COX activity could
contribute to systemic inflammation. In fact, inhibition
of COX results in decreased production of the pro-
inflammatory cytokines, TNF-α, IL-6 and IL-1ß in LPS-
stimulated macrophages [43] and aspirin administration
reduces plasma IL-1ß and IL-6 in patients with metabolic
syndrome [44]. Thus, the potent inhibitory effect of DAPS
on COX activity likely accounts for the marked reduction
of inflammatory cytokine elevation induced by LPS in rats.
However, the non-significant reduction of IL-6 and IL-1ß
and the significant reduction of TNF-α increase in LPS-
stimulated rats by DHPS suggest a positive modulation by
FGF in inflammatory cytokine elevation. This would be
consistent with evidences showing that FGF-1 stimulates
cytokine production in Jurkat T-cells via NF-кB activation
[45], while FGFR2 activation by FGF-1 potentiates the
secretion of TNF-α and IL-6 in LPS/INFγ-stimulated hu-
man astrocytes and microglia [46].
It may be somewhat surprising that an FGF inhibitor
can exhibit so good a safety profile as DHPS (dobesilate)
[10], given the broad spectrum of physiological activities
in which FGFs are involved [47]. FGFs have been de-
scribed in most adult tissues derived from the embryonic
mesoderm and neuroectoderm, where they are tightly
bound to the sulfated glycosaminoglycans of the extra-
cellular matrix, sometimes at very high levels [48]. Al-
though initially described as FGF traps and protectors,
these proteoglycans were later found to participate in
FGF signaling [49,50]. Thus, under normal physiological
conditions FGFs do not act as signaling molecules in so-
lution but rather, as solid-phase-like growth factors [51].
As long as FGFs remain part of the extracellular matrix,
they cannot be inhibited by dobesilate, which has an
affinity constant for FGF approximately 3,000 times
lower than that of the sulfated glycosaminoglycans of
the extracellular matrix, which can reach extraordinarily
high local concentrations [13]. However, the physio-
logical FGF signaling system can be subverted when high
concentrations of free FGF accumulate, resulting in
serious physiological disturbances, either through un-
controlled synthesis or mobilization by heparanases and
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Figure 7 Effects of oral administration of potassium 2,5-diacetoxyphenyl sulfonate (DAPS) on the progression, angiogenesis and
apoptosis of tumors established in rats by subcutaneous implantation of rat glioma C6 cells (5 × 105 cells). Treatment began once the
presence of a tumor was verified on the fifth day after glioma cell implantation (arrow in panel A). Tumors were removed after 10 days of
treatment with vehicle (VEH, tap water; n = 8) or DAPS (200 mg/kg/d; eq. to 0.73 mmol/kg/d; n = 10) by oral gavage. Panel A shows the time-course of
subcutaneous glioma size in rats treated with vehicle or DAPS. Panel B shows representative images of macroscopic aspect of tumors excised from
rats treated with vehicle or DAPS while the quantification and comparison of the volumes and weights are shown in the same row. Panel C shows
representative images illustrating the intense leukocyte extravasation and infiltration observed in peritumoral vessels of gliomas obtained from
vehicle-treated rats that is markedly reduced in gliomas from rats treated with DAPS. Panel D shows representative images illustrating the intense
vascularization in tumors from vehicle-treated rats which is notably reduced in DAPS-treated rats, as confirmed by functional vessel quantification
displayed at the right side. Panel E shows representative images illustrating the scarce presence of apoptotic nuclei detected by TUNEL assay in
sections of tumors from vehicle-treated rats that markedly increased in DAPS-treated rats, as confirmed by quantification of the percentage of tumoral
apoptotic nuclei displayed at the right side. The data are expressed as the mean ± SEM: *p < 0.05; **p < 0.01; ***p < 0.001 vs. VEH by unpaired
Student’s t test.
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efficiently inhibited by dobesilate [13], which mainly pro-
vokes the inhibition of pathological FGF, leaving the
physiological FGF pool relatively unchanged.
Our in vivo assays demonstrated that despite being a
poorer in vitro inhibitor of FGF than DHPS, DAPS is
more effective in inhibiting FGF-1-induced angiogenesis.
However, it should be noted that angiogenesis in the
implanted sponges appeared to be a consequence of FGF-
evoked inflammation, and that inflammatory chemokines
and inflammatory cells are early mediators of FGF-driven
angiogenesis both in vivo and during neovascularization,
according to the expression profile of FGF-stimulated
microvascular cells [14,55,56]. Indeed, the induction and
inhibition of FGF-driven angiogenesis in vivo was consis-
tently associated with an increase and decrease in inflam-
matory cell infiltration of the implanted gelatin sponges,
respectively [29]. The superiority of DAPS as an anti-
angiogenic drug is probably due to its COX-related anti-
inflammatory activity, a view consistent with the active
role of COX and PG synthesis in angiogenesis [57,58].
The efficacy of DHPS in inhibiting glioma growth in
both heterotopic and orthotopic models has been de-
monstrated previously [13,18]. Unlike xenograft models
in immunosuppressed animals, rats bearing gliomas in
these models have an intact immune system, which is an
important distinction as inflammation is generally ac-
cepted to play a critical role in tumorigenesis [59,60].
Most solid malignancies trigger intrinsic inflammatory
responses that promote a pro-tumorigenic microen-
vironment [61]. Furthermore, COX and the products of
its activity are specifically involved in carcinogenesis
[62-64]. In fact, COX inhibition has been recently re-
ported to potentiate anti-angiogenic cancer therapy in
preclinical models [65]. COX was indeed proposed to be
a therapeutic target for the treatment of gliomas [66,67].
The participation of COX in tumoral processes may ex-
plain the superior efficacy of DAPS in inhibiting theprogression of subcutaneous gliomas, which in some
cases even resulted in the complete regression of estab-
lished tumors. In addition, it should be noted that the
efficacy of DAPS to inhibit angiogenesis and tumor pro-
gression is also demonstrated when orally administered,
increasing its potential therapeutic relevance. Further-
more, oral treatment with DAPS does not prevent nor-
mal weight gain in rats which points to the absence of
dramatic toxicity under these experimental conditions.
Histological analyses of the tumors suggest that the in-
hibition of tumoral progression by DAPS is related to its
capacity to reduce angiogenesis and to promote apop-
tosis, two hallmarks of glioma progression [24]. FGF
contributes to both processes as demonstrated by the in-
hibition of angiogenesis and apoptosis by DHPS in
orthotopic experimental gliomas [18]. In fact, an intense
leukocyte infiltration is observed in peritumoral vessels
of subcutaneous gliomas However COX activity seems
to be involved in angiogenesis and glioma cell survival
(escape from apoptosis) [68,69] supporting dual FGF/
COX inhibition by DAPS as a reasonable strategy to in-
hibit glioma progression.Conclusions
The present results support a role for FGF in inflam-
mation and indicate a potential therapeutic role of FGF
inhibitors such as DHPS in inflammatory processes. In
addition, we demonstrate that a simple modification of
DHPS by acetylating hydroxyl residues in the phenyl
ring yields a new compound, DAPS, which inhibits COX
while maintaining substantial FGF inhibitory activity, a
characteristic that enhances its anti-inflammatory acti-
vity. This modification converts DAPS into a superior
oral inhibitor of angiogenesis and tumor progression
than DHPS and represents a reasonable strategy to com-
bat tumoral processes as well as other inflammation-
and angiogenesis-related diseases.
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